BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 26626718)

  • 1. Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentration.
    Strukova EN; Portnoy YA; Zinner SH; Firsov AA
    J Antimicrob Chemother; 2016 Mar; 71(3):678-84. PubMed ID: 26626718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Searching for the Optimal Predictor of Ciprofloxacin Resistance in Klebsiella pneumoniae by Using In Vitro Dynamic Models.
    Strukova EN; Portnoy YA; Romanov AV; Edelstein MV; Zinner SH; Firsov AA
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1208-15. PubMed ID: 26643328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacterial antibiotic resistance studies using in vitro dynamic models: Population analysis vs. susceptibility testing as endpoints of mutant enrichment.
    Firsov AA; Strukova EN; Portnoy YA; Shlykova DS; Zinner SH
    Int J Antimicrob Agents; 2015 Sep; 46(3):313-8. PubMed ID: 26297633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion.
    Firsov AA; Smirnova MV; Strukova EN; Vostrov SN; Portnoy YA; Zinner SH
    Int J Antimicrob Agents; 2008 Dec; 32(6):488-93. PubMed ID: 18790614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacterial resistance studies using in vitro dynamic models: the predictive power of the mutant prevention and minimum inhibitory antibiotic concentrations.
    Firsov AA; Strukova EN; Shlykova DS; Portnoy YA; Kozyreva VK; Edelstein MV; Dovzhenko SA; Kobrin MB; Zinner SH
    Antimicrob Agents Chemother; 2013 Oct; 57(10):4956-62. PubMed ID: 23896481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concentration-resistance relationships with Pseudomonas aeruginosa exposed to doripenem and ciprofloxacin in an in vitro model.
    Zinner SH; Gilbert D; Greer K; Portnoy YA; Firsov AA
    J Antimicrob Chemother; 2013 Apr; 68(4):881-7. PubMed ID: 23175594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.
    Firsov AA; Smirnova MV; Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH
    J Antimicrob Chemother; 2006 Dec; 58(6):1185-92. PubMed ID: 17028094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting bacterial resistance using the time inside the mutant selection window: possibilities and limitations.
    Firsov AA; Portnoy YA; Strukova EN; Shlykova DS; Zinner SH
    Int J Antimicrob Agents; 2014 Oct; 44(4):301-5. PubMed ID: 25218155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time inside the mutant selection window as a predictor of staphylococcal resistance to linezolid.
    Alieva KN; Strukova EN; Golikova MV; Portnoy YA; Zinner SH; Firsov AA
    J Antibiot (Tokyo); 2018 May; 71(5):514-521. PubMed ID: 29348530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Species differences in ciprofloxacin resistance among Gram-negative bacteria: can "anti-mutant" ratios of the area under the concentration-time curve to the MIC be achieved clinically?
    Strukova EN; Portnoy YA; Zinner SH; Firsov AA
    J Chemother; 2017 Dec; 29(6):351-357. PubMed ID: 28587559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing.
    Zinner SH; Lubenko IY; Gilbert D; Simmons K; Zhao X; Drlica K; Firsov AA
    J Antimicrob Chemother; 2003 Oct; 52(4):616-22. PubMed ID: 12951352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to linezolid in an in vitro dynamic model.
    Firsov AA; Alieva KN; Strukova EN; Golikova MV; Portnoy YA; Dovzhenko SA; Kobrin MB; Romanov AV; Edelstein MV; Zinner SH
    J Antimicrob Chemother; 2017 Nov; 72(11):3100-3107. PubMed ID: 28981793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro resistance studies with bacteria that exhibit low mutation frequencies: prediction of "antimutant" linezolid concentrations using a mixed inoculum containing both susceptible and resistant Staphylococcus aureus.
    Firsov AA; Golikova MV; Strukova EN; Portnoy YA; Romanov AV; Edelstein MV; Zinner SH
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1014-9. PubMed ID: 25451050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration.
    Olofsson SK; Marcusson LL; Komp Lindgren P; Hughes D; Cars O
    J Antimicrob Chemother; 2006 Jun; 57(6):1116-21. PubMed ID: 16624874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic modeling of risk factors for ciprofloxacin resistance in Pseudomonas aeruginosa.
    Hyatt JM; Schentag JJ
    Infect Control Hosp Epidemiol; 2000 Jan; 21(1 Suppl):S9-11. PubMed ID: 10654629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa].
    Liu MT; Sheng MY; Zhang Y; Li Y
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1427-31. PubMed ID: 21756818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.
    Pasquali F; Manfreda G
    Vet Microbiol; 2007 Jan; 119(2-4):304-10. PubMed ID: 16987619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model.
    Firsov AA; Vostrov SN; Lubenko IY; Arzamastsev AP; Portnoy YA; Zinner SH
    J Antimicrob Chemother; 2004 Jul; 54(1):178-86. PubMed ID: 15190041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shape does matter: short high-concentration exposure minimizes resistance emergence for fluoroquinolones in Pseudomonas aeruginosa.
    Rees VE; Bulitta JB; Nation RL; Tsuji BT; Sörgel F; Landersdorfer CB
    J Antimicrob Chemother; 2015 Mar; 70(3):818-26. PubMed ID: 25381167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window.
    Firsov AA; Lubenko IY; Smirnova MV; Strukova EN; Zinner SH
    Antimicrob Agents Chemother; 2008 Jun; 52(6):1924-8. PubMed ID: 18378704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.